Triasima Portfolio Management inc. Grows Stock Position in Boston Scientific Corporation $BSX

Triasima Portfolio Management inc. lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 4.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,484 shares of the medical equipment provider’s stock after buying an additional 1,915 shares during the period. Triasima Portfolio Management inc.’s holdings in Boston Scientific were worth $4,993,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of BSX. Vanguard Group Inc. increased its holdings in shares of Boston Scientific by 1.3% in the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock worth $13,577,311,000 after buying an additional 1,697,945 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Boston Scientific by 18.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock worth $1,070,387,000 after buying an additional 1,664,108 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Boston Scientific by 161.9% in the first quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider’s stock worth $250,757,000 after buying an additional 1,536,663 shares during the period. Swedbank AB increased its holdings in shares of Boston Scientific by 114.5% in the second quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock worth $302,816,000 after buying an additional 1,505,019 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Boston Scientific by 10.8% in the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after buying an additional 1,383,524 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 0.9%

BSX stock opened at $95.86 on Wednesday. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The business’s 50 day moving average price is $102.53 and its two-hundred day moving average price is $101.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The company has a market capitalization of $142.05 billion, a price-to-earnings ratio of 57.06, a price-to-earnings-growth ratio of 2.33 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the prior year, the business earned $0.62 EPS. The business’s revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $18,659,923.46. The trade was a 21.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $17,972,457 over the last quarter. Insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on BSX. Erste Group Bank downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Leerink Partnrs upgraded Boston Scientific to a “strong-buy” rating in a report on Monday, June 16th. BTIG Research boosted their price target on Boston Scientific from $127.00 to $132.00 and gave the company a “buy” rating in a report on Wednesday, October 1st. Canaccord Genuity Group boosted their price target on Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a report on Wednesday, October 1st. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $125.00 price target on shares of Boston Scientific in a report on Monday, September 29th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $120.71.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.